DocWire News Editors

DocwireNews

The&nbsp;<a href="https://proddocwire.wpengine.com/tag/cardiovascular-risk/">cardiovascular</a>&nbsp;(CV) and renal outcomes of glucose-lowering therapy with canagliflozin were not affected by baseline levels of kidney function in patients with&nbsp;<a href="https://proddocwire.wpengine.com/tag/type-2-diabetes/">type 2 diabetes</a>, a new analysis of the CANVAS trial reports.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Researchers randomized 10,142 patients with type 2 diabetes and estimated glomerular filtration rate (eGFR) &gt;30 mL/min/1.73 m2&nbsp;to receive either canagliflozin or placebo. The primary outcome of interest was composite CV death, nonfatal myocardial infarction, or nonfatal stroke, as well as other CV and renal outcomes. The current analysis focused on outcomes in patients with chronic kidney disease (eGFR &lt;60 and &ge;60 mL/min/1.73 m2) and according to baseline kidney&nbsp;function (eGFR &lt;45, 45 to &lt;60, 60 to &lt;90, and &ge;90 mL/min/1.73 m2).&nbsp;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Canagliflozin consistently prevents CV and renal outcomes across different levels of kidney function <a href="https://twitter.com/brendonneuen?ref_src=twsrc%5Etfw">@brendonneuen</a> <a href="https://twitter.com/VladoPerkovic?ref_src=twsrc%5Etfw">@VladoPerkovic</a> <a href="https://twitter.com/georgeinstitute?ref_src=twsrc%5Etfw">@georgeinstitute</a> <a href="https://t.co/eli7AiNQaQ">https://t.co/eli7AiNQaQ</a> <a href="https://t.co/npPMfeZvuJ">pic.twitter.com/npPMfeZvuJ</a>
&mdash; Circulation (@CircAHA) <a href="https://twitter.com/CircAHA/status/1011323264738775040?ref_src=twsrc%5Etfw">June 25, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>According to the study results, canagliflozin did not affect the primary study outcomes in patients with chronic kidney disease (HR=0.70; 95% CI, 0.55 to 0.90)&nbsp;and&nbsp;also&nbsp;in patients with preserved kidney&nbsp;function (HR=0.92; 95% CI, 0.79 to 1.07). The study also reported similar relative effects on CV and renal&nbsp;outcomes&nbsp;across all eGFR subgroups.&nbsp;&ldquo;The effects of canagliflozin on cardiovascular and renal outcomes were not modified by baseline level of kidney function in people with type 2 diabetes and a history or high risk of cardiovascular disease down to eGFR levels of 30 mL/min/1.73 m2,&rdquo; the authors wrote in their conclusion. &ldquo;Reassessing current limitations on the use of canagliflozin in chronic kidney disease may allow additional individuals to benefit from this therapy.&rdquo;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
I see it&rsquo;s up now! <a href="https://t.co/YZvh2MnPFn">https://t.co/YZvh2MnPFn</a> CANVAS results by baseline kidney function in <a href="https://twitter.com/CircAHA?ref_src=twsrc%5Etfw">@CircAHA</a> &amp; <a href="https://twitter.com/hashtag/2018ADA?src=hash&amp;ref_src=twsrc%5Etfw">#2018ADA</a> from <a href="https://twitter.com/brendonneuen?ref_src=twsrc%5Etfw">@brendonneuen</a> &amp; <a href="https://twitter.com/VladoPerkovic?ref_src=twsrc%5Etfw">@VladoPerkovic</a> et al <a href="https://t.co/Q0ddHFre6Y">https://t.co/Q0ddHFre6Y</a>
&mdash; Swapnil Hiremath @hswapnil@bsky.social (@hswapnil) <a href="https://twitter.com/hswapnil/status/1011237783405355008?ref_src=twsrc%5Etfw">June 25, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Our paper now parallel published in <a href="https://twitter.com/CircAHA?ref_src=twsrc%5Etfw">@CircAHA</a> for <a href="https://twitter.com/hashtag/2018ADA?src=hash&amp;ref_src=twsrc%5Etfw">#2018ADA</a>!
*Open access*
Cardiovascular &amp; renal outcomes with canagliflozin by baseline kidney function: data from the CANVAS Program<a href="https://twitter.com/hashtag/VisualAbstract?src=hash&amp;ref_src=twsrc%5Etfw">#VisualAbstract</a>
Link: <a href="https://t.co/uLM6GICvbe">https://t.co/uLM6GICvbe</a>
Next: TWEETORIAL summary of the paper (1/9) <a href="https://t.co/Qp0SMn5obO">pic.twitter.com/Qp0SMn5obO</a>
&mdash; Brendon Neuen (@brendonneuen) <a href="https://twitter.com/brendonneuen/status/1011260490977370116?ref_src=twsrc%5Etfw">June 25, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
The effect of canagliflozin on cardiovascular and renal outcomes is not modified by baseline level of kidney function in T2DM. This reinforces the safety of cana in CKD <a href="https://t.co/f3vkNNHHNW">https://t.co/f3vkNNHHNW</a>
&mdash; Belen Perez Pevida (@perezpevida_B) <a href="https://twitter.com/perezpevida_B/status/1011497906703085568?ref_src=twsrc%5Etfw">June 26, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
How low can you go? Down to eGFR of 30 for <a href="https://twitter.com/hashtag/CVD?src=hash&amp;ref_src=twsrc%5Etfw">#CVD</a> <a href="https://twitter.com/hashtag/CKD?src=hash&amp;ref_src=twsrc%5Etfw">#CKD</a> benefit <a href="https://t.co/OnFboroUWn">https://t.co/OnFboroUWn</a>
&mdash; Daniel J Drucker (@DanielJDrucker) <a href="https://twitter.com/DanielJDrucker/status/1011238857298382850?ref_src=twsrc%5Etfw">June 25, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Congrats for an important manuscript ! <a href="https://t.co/JsUBpHXdZ1">https://t.co/JsUBpHXdZ1</a>
&mdash; Prof Gemma Figtree AM (@gemtreee) <a href="https://twitter.com/gemtreee/status/1019136158377263104?ref_src=twsrc%5Etfw">July 17, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Well done <a href="https://twitter.com/brendonneuen?ref_src=twsrc%5Etfw">@brendonneuen</a> !! Major contribution and a terrific background for the CREDENCE and DAPA-CKD <a href="https://t.co/ylCLGM1nF7">https://t.co/ylCLGM1nF7</a>
&mdash; Roberto Pecoits-Filho (@pecoitsfilho) <a href="https://twitter.com/pecoitsfilho/status/1012682901052428288?ref_src=twsrc%5Etfw">June 29, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Source: <a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.035901">Circulation</a>

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Baseline Kidney Function Does Not Affect CV or Renal Outcomes for Canagliflozin

Cardiology

The cardiovascular (CV) and renal outcomes of glucose-lowering therapy with canagliflozin were not affected by baseline levels of kidney function in patients with type 2 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe